StockWatch
·
Q2 FY-2027 RESULTS · GLAND

Gland Pharma Q2 FY27: Consolidated PAT up 58% YoY to ₹291 Cr, margins expand, beats Street

PAT +58.29% YoY · revenue +23.32% · margins expanding · beat vs street

Q2 FY27 resultsGLANDGland Pharma Ltd06 Nov 2026 · 3 min read
Revenue

₹1,833.59 Cr

+23.32% YoY

PAT (consolidated)

₹290.76 Cr

+58.29% YoY

Net margin

15.28%

+3.6pp YoY

EPS

₹17.62

Gland Pharma's consolidated revenue rose 23% YoY to ₹1,834 Cr in Q2 FY27 (quarter ended September 30, 2026), with PAT climbing 58% YoY to ₹291 Cr and EPS at ₹17.62 against ₹11.15 a year ago. Both lines came in ahead of Street consensus (GuruFocus) of ~₹1,769 Cr revenue and ₹17.10 EPS — a beat of roughly 3-4% on each. Sequentially the picture cooled: revenue was up just 2% QoQ and PAT fell 8% QoQ from the June quarter's ₹317 Cr, with EBITDA margin easing to 26% (adj. 27%) from 27% (adj. 28%) and PAT margin slipping to 16% from 18%. The YoY read, not the softer sequential print, is the one that should anchor the verdict here.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹1,833.59 Cr+1.9%+23.3%
Expenses₹1,471.69 Cr+3.2%+14.3%
PAT₹290.76 Cr-8.27%+58.29%
Net margin15.28%-1.8pp+3.6pp
EPS₹17.62-8.4%+58%

The YoY margin expansion — EBITDA margin up from 21% to 26%, PAT margin up ~350bps to 16% — was driven by the CDMO business, which grew 31% YoY to ₹823 Cr (45% of sales) on expanding customer engagements and strategic partnerships, outpacing Critical Injectables' 18% YoY growth to ₹1,011 Cr. Geographically the US remained the engine, up 42% YoY to ₹1,180 Cr (64% of revenue), with Europe up 30% YoY to ₹371 Cr, while India (-42% YoY) and other core/rest-of-world markets all declined — a mix shift toward the higher-margin CDMO/US franchise. R&D spend rose to ₹108 Cr (6% of revenue, from 5%) as the company filed 11 ANDAs with 10 approvals in the quarter (cumulative 399 filed, 350 approved) and launched four molecules — Sugammadex, Erythromycin, Fluorouracil and Atropine sulfate — in the US.

₹
2,470.162,663.762,857.353,050.943,244.543,169.608-0308-2509-1710-1211-0411-06Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹3,169.6, up 0.6% over the past month of trading.

₹ Cr
0136.89273.78410.68215.48Q1 FY26rev ₹1,506 Cr183.68Q2 FY26rev ₹1,487 Cr261.48Q3 FY26rev ₹1,695 Cr366.68Q4 FY26rev ₹1,743 Cr316.96Q1 FY27rev ₹1,800 Cr290.76Q2 FY27rev ₹1,834 Cr
Quarterly consolidated PAT, ₹ Crore
Beyond the headline

What the summary numbers don't show

Standalone PAT of ₹425 Cr sits well above consolidated ₹291 Cr, reflecting the continuing drag from European subsidiaries (Cenexi group) below the standalone level

What management guided (1 FY-2027 call)
FY27 constant currency revenue growth 15% (raised from 12-13%); EBITDA margins 30% near-term (raised from 25-26%), targeting 35% long-term. Large USD 90-100M CDMO contract starting CY2029. Next 4-year CAGR ~20%.

— This quarter: beat

Revenue growth of 23% YoY comfortably clears management's FY27 guidance of 15% constant-currency growth (raised twice this year, from 12-13%), but the 26% EBITDA margin still trails the 30% near-term margin target reiterated on the same call — a guidance beat on growth, work-in-progress on margin. Executive Chairman Srinivas Sadu framed the quarter as "another quarter of strong growth... driven by strong execution across our businesses," citing CDMO's 31% YoY growth and a "robust opportunity pipeline" — a framing the numbers support on growth but only partially on margin, which remains below the company's own target. During the quarter the company also disclosed a USFDA inspection at its Dundigal facility concluding with four procedural observations (VSEZ had zero), received USFDA approval for Methylprednisolone injectable, and — just after quarter-end — agreed to subscribe to 60% of Novelstar Pharma Inc. in the US for $21M, adding a step-down subsidiary.

  • W1

    Whether adj. EBITDA margin (26-27% currently) re-accelerates toward management's 30% near-term / 35% long-term targets

  • W2

    Progress on the ~$90-100M CDMO contract slated to start CY2029 and the 15 products in co-development (commercialization targeted FY29)

  • W3

    Contribution of the newly acquired 60% stake in Novelstar Pharma Inc. (US, effective Nov 1, 2026) to future US revenue

Figures converted from ₹ million in source (÷10). No exceptional items in the Q2 FY27 or Q2 FY26 columns (FY26's ₹24.3 Cr New Labour Code provision sits in the Dec-25 quarter/FY26 full-year column only), so YoY PAT growth is unadjusted/clean. Standalone PAT (₹424.9 Cr) exceeds consolidated (₹290.8 Cr) due to European subsidiaries (Cenexi group) consolidated below the standalone level — a recurring feature, not a one-off divergence.

Informational and educational content only. Not investment advice.